A novel antibody therapy against non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease is strongly associated with poor nutrition and obesity, often leading to non-alcoholic steatohepatitis (NASH), fibrosis and liver cancer. Anti-platelet therapy has emerged as a potential strategy against NASH but exhibits adverse health effects. Researchers of the EU-funded FAITH project have previously shown that blocking the platelet-derived surface molecule GPIba prevents NASH and liver cancer in experimental models without any side effects. With this project, they plan to generate antibodies to block the binding of thrombin to GPIba without interfering with its role in platelet-derived aggregation and haemostasis.
Fields of science
Funding SchemeERC-POC - Proof of Concept Grant
See on map